 Aileron Therapeutics ALRN today announced plans to report interim results from their Phase 1b2 clinical trial of ALRN-6924 in small cell lung cancer SCLC. In this trial, ALRN-6924 is being evaluated as an agent to protect cancer patients against chemotherapy-induced toxicity, a concept known as myelopreservation or chemoprotection. 